Compare Stocks: SLN, NAMS, CLDX, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.32 -3.8%	$29.84	$16.02 ▼ $38.26	$3.03B	2.23	1.66 million shs	1.33 million shs
CLDX Celldex Therapeutics	$39.12 -3.3%	$38.51	$21.71 ▼ $45.14	$3.07B	0.87	868,254 shs	424,938 shs
NAMS NewAmsterdam Pharma	$25.90 -3.3%	$30.33	$23.05 ▼ $42.21	$3.10B	0.1	1.13 million shs	1.04 million shs
SLN Silence Therapeutics	$13.42 -0.2%	$11.49	$4.19 ▼ $17.58	$808.01M	1.39	1.90 million shs	539,702 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-1.48%	+10.68%	-10.96%	+73.90%
CLDX Celldex Therapeutics	0.00%	-3.12%	+1.64%	+24.47%	+73.10%
NAMS NewAmsterdam Pharma	0.00%	-7.07%	-9.00%	-23.10%	+5.84%
SLN Silence Therapeutics	0.00%	+1.13%	+15.49%	+94.49%	+158.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$29.32 -3.8%	$29.84	$16.02 ▼ $38.26	$3.03B	2.23	1.66 million shs	1.33 million shs
CLDX Celldex Therapeutics	$39.12 -3.3%	$38.51	$21.71 ▼ $45.14	$3.07B	0.87	868,254 shs	424,938 shs
NAMS NewAmsterdam Pharma	$25.90 -3.3%	$30.33	$23.05 ▼ $42.21	$3.10B	0.1	1.13 million shs	1.04 million shs
SLN Silence Therapeutics	$13.42 -0.2%	$11.49	$4.19 ▼ $17.58	$808.01M	1.39	1.90 million shs	539,702 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-1.48%	+10.68%	-10.96%	+73.90%
CLDX Celldex Therapeutics	0.00%	-3.12%	+1.64%	+24.47%	+73.10%
NAMS NewAmsterdam Pharma	0.00%	-7.07%	-9.00%	-23.10%	+5.84%
SLN Silence Therapeutics	0.00%	+1.13%	+15.49%	+94.49%	+158.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	67.12% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.08	43.36% Upside
NAMS NewAmsterdam Pharma	2.92	Moderate Buy	$49.73	92.00% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	298.66% Upside

Current Analyst Ratings Breakdown

Latest SLN, NAMS, CLDX, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/6/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
7/29/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $72.00
7/22/2026	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$54.00 ➝ $48.00
7/22/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
7/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$67.00 ➝ $61.00
7/22/2026	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$62.00 ➝ $60.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$156.04M	19.41	N/A	N/A	$10.34 per share	2.84
CLDX Celldex Therapeutics	$158K	19,443.63	N/A	N/A	$9.10 per share	4.30
NAMS NewAmsterdam Pharma	$22.50M	137.60	N/A	N/A	$5.28 per share	4.91
SLN Silence Therapeutics	$615K	1,313.83	N/A	N/A	$0.64 per share	20.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest SLN, NAMS, CLDX, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.07%	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CLDX Celldex Therapeutics	N/A	11.82	11.82
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CLDX Celldex Therapeutics	N/A
NAMS NewAmsterdam Pharma	89.89%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CLDX Celldex Therapeutics	5.20%
NAMS NewAmsterdam Pharma	12.74%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
NAMS NewAmsterdam Pharma	4	119.54 million	104.31 million	Optionable
SLN Silence Therapeutics	100	60.21 million	58.40 million	Not Optionable

SLN, NAMS, CLDX, and BEAM Headlines

Recent News About These Companies

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

August 26, 2026 | marketbeat.com

Research Analysts Issue Forecasts for SLN Q3 Earnings

August 20, 2026 | americanbankingnews.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?

August 18, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SLN Q3 Earnings?

August 18, 2026 | marketbeat.com

Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN)

August 17, 2026 | marketbeat.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?

August 12, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume - What's Next?

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints

August 10, 2026 | finance.yahoo.com

Silence Therapeutics stock surges as divesiran trial results fuel optimism

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, NAMS, CLDX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$29.32 -1.16 (-3.81%)

As of 08/28/2026 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$39.12 -1.34 (-3.31%)

As of 08/28/2026 04:00 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

NewAmsterdam Pharma NASDAQ:NAMS

$25.90 -0.89 (-3.32%)

As of 08/28/2026 04:00 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Silence Therapeutics NASDAQ:SLN

$13.42 -0.03 (-0.22%)

As of 08/28/2026 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, NAMS, CLDX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, NAMS, CLDX, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, NAMS, CLDX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, NAMS, CLDX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

NewAmsterdam Pharma NASDAQ:NAMS

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, NAMS, CLDX, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, NAMS, CLDX, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, NAMS, CLDX, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, NAMS, CLDX, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

NewAmsterdam Pharma NASDAQ:NAMS

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools